16 September 2025NewsAsiaMarisa Woutersen

To disclose or not: Pharma patents face new AI reality

From drug discovery to post-market surveillance, AI is rewriting the rules in pharma—and the patent system is struggling to keep up. At AIPPI’s World Congress 2025, Marisa Woutersen hears experts debate AI disclosure, inventive step, and inventorship.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
24 April 2025   Generative AI is transforming the biotech industry, so it’s crucial to have an IP strategy—in particular, for trade secret and/or patent protection. Dean Pelletier of Pelletier Law explains.
Americas
24 October 2024   Counsel from Pfizer, Gilead, and Bristol Myers Squibb spoke on AI’s transformative power and risks, reports Marisa Woutersen at LSPN Fall North America.
Biotechnology
25 January 2024   Despite the clamour for guidance, applicants, attorneys, and lawyers may be in for a frustrating wait before the UK updates AI protections, says Rebecca Lawrence of DLA Piper.